1120 related articles for article (PubMed ID: 28314689)
1. DNA methylation-based classification and grading system for meningioma: a multicentre, retrospective analysis.
Sahm F; Schrimpf D; Stichel D; Jones DTW; Hielscher T; Schefzyk S; Okonechnikov K; Koelsche C; Reuss DE; Capper D; Sturm D; Wirsching HG; Berghoff AS; Baumgarten P; Kratz A; Huang K; Wefers AK; Hovestadt V; Sill M; Ellis HP; Kurian KM; Okuducu AF; Jungk C; Drueschler K; Schick M; Bewerunge-Hudler M; Mawrin C; Seiz-Rosenhagen M; Ketter R; Simon M; Westphal M; Lamszus K; Becker A; Koch A; Schittenhelm J; Rushing EJ; Collins VP; Brehmer S; Chavez L; Platten M; Hänggi D; Unterberg A; Paulus W; Wick W; Pfister SM; Mittelbronn M; Preusser M; Herold-Mende C; Weller M; von Deimling A
Lancet Oncol; 2017 May; 18(5):682-694. PubMed ID: 28314689
[TBL] [Abstract][Full Text] [Related]
2. Distinct genomic subclasses of high-grade/progressive meningiomas: NF2-associated, NF2-exclusive, and NF2-agnostic.
Williams EA; Santagata S; Wakimoto H; Shankar GM; Barker FG; Sharaf R; Reddy A; Spear P; Alexander BM; Ross JS; Brastianos PK; Cahill DP; Ramkissoon SH; Juratli TA
Acta Neuropathol Commun; 2020 Oct; 8(1):171. PubMed ID: 33087175
[TBL] [Abstract][Full Text] [Related]
3. Mutational patterns and regulatory networks in epigenetic subgroups of meningioma.
Paramasivam N; Hübschmann D; Toprak UH; Ishaque N; Neidert M; Schrimpf D; Stichel D; Reuss D; Sievers P; Reinhardt A; Wefers AK; Jones DTW; Gu Z; Werner J; Uhrig S; Wirsching HG; Schick M; Bewerunge-Hudler M; Beck K; Brehmer S; Urbschat S; Seiz-Rosenhagen M; Hänggi D; Herold-Mende C; Ketter R; Eils R; Ram Z; Pfister SM; Wick W; Weller M; Grossmann R; von Deimling A; Schlesner M; Sahm F
Acta Neuropathol; 2019 Aug; 138(2):295-308. PubMed ID: 31069492
[TBL] [Abstract][Full Text] [Related]
4. Genomic analysis of non-NF2 meningiomas reveals mutations in TRAF7, KLF4, AKT1, and SMO.
Clark VE; Erson-Omay EZ; Serin A; Yin J; Cotney J; Ozduman K; Avşar T; Li J; Murray PB; Henegariu O; Yilmaz S; Günel JM; Carrión-Grant G; Yilmaz B; Grady C; Tanrikulu B; Bakircioğlu M; Kaymakçalan H; Caglayan AO; Sencar L; Ceyhun E; Atik AF; Bayri Y; Bai H; Kolb LE; Hebert RM; Omay SB; Mishra-Gorur K; Choi M; Overton JD; Holland EC; Mane S; State MW; Bilgüvar K; Baehring JM; Gutin PH; Piepmeier JM; Vortmeyer A; Brennan CW; Pamir MN; Kiliç T; Lifton RP; Noonan JP; Yasuno K; Günel M
Science; 2013 Mar; 339(6123):1077-80. PubMed ID: 23348505
[TBL] [Abstract][Full Text] [Related]
5. SMO mutation status defines a distinct and frequent molecular subgroup in olfactory groove meningiomas.
Boetto J; Bielle F; Sanson M; Peyre M; Kalamarides M
Neuro Oncol; 2017 Mar; 19(3):345-351. PubMed ID: 28082415
[TBL] [Abstract][Full Text] [Related]
6. Genetic landscape of meningioma.
Yuzawa S; Nishihara H; Tanaka S
Brain Tumor Pathol; 2016 Oct; 33(4):237-247. PubMed ID: 27624470
[TBL] [Abstract][Full Text] [Related]
7. An integrated genomic analysis of anaplastic meningioma identifies prognostic molecular signatures.
Collord G; Tarpey P; Kurbatova N; Martincorena I; Moran S; Castro M; Nagy T; Bignell G; Maura F; Young MD; Berna J; Tubio JMC; McMurran CE; Young AMH; Sanders M; Noorani I; Price SJ; Watts C; Leipnitz E; Kirsch M; Schackert G; Pearson D; Devadass A; Ram Z; Collins VP; Allinson K; Jenkinson MD; Zakaria R; Syed K; Hanemann CO; Dunn J; McDermott MW; Kirollos RW; Vassiliou GS; Esteller M; Behjati S; Brazma A; Santarius T; McDermott U
Sci Rep; 2018 Sep; 8(1):13537. PubMed ID: 30202034
[TBL] [Abstract][Full Text] [Related]
8. Loss of histone H3K27me3 identifies a subset of meningiomas with increased risk of recurrence.
Katz LM; Hielscher T; Liechty B; Silverman J; Zagzag D; Sen R; Wu P; Golfinos JG; Reuss D; Neidert MC; Wirsching HG; Baumgarten P; Herold-Mende C; Wick W; Harter PN; Weller M; von Deimling A; Snuderl M; Sen C; Sahm F
Acta Neuropathol; 2018 Jun; 135(6):955-963. PubMed ID: 29627952
[TBL] [Abstract][Full Text] [Related]
9. Novel molecular subgroups for clinical classification and outcome prediction in childhood medulloblastoma: a cohort study.
Schwalbe EC; Lindsey JC; Nakjang S; Crosier S; Smith AJ; Hicks D; Rafiee G; Hill RM; Iliasova A; Stone T; Pizer B; Michalski A; Joshi A; Wharton SB; Jacques TS; Bailey S; Williamson D; Clifford SC
Lancet Oncol; 2017 Jul; 18(7):958-971. PubMed ID: 28545823
[TBL] [Abstract][Full Text] [Related]
10. Triple approach for diagnosis and grading of meningiomas: histology, morphometry of Ki-67/Feulgen stainings, and cytogenetics.
Kolles H; Niedermayer I; Schmitt C; Henn W; Feld R; Steudel WI; Zang KD; Feiden W
Acta Neurochir (Wien); 1995; 137(3-4):174-81. PubMed ID: 8789658
[TBL] [Abstract][Full Text] [Related]
11. Molecular biological determinations of meningioma progression and recurrence.
Linsler S; Kraemer D; Driess C; Oertel J; Kammers K; Rahnenführer J; Ketter R; Urbschat S
PLoS One; 2014; 9(4):e94987. PubMed ID: 24722350
[TBL] [Abstract][Full Text] [Related]
12. Clinical impact of targeted amplicon sequencing for meningioma as a practical clinical-sequencing system.
Yuzawa S; Nishihara H; Yamaguchi S; Mohri H; Wang L; Kimura T; Tsuda M; Tanino M; Kobayashi H; Terasaka S; Houkin K; Sato N; Tanaka S
Mod Pathol; 2016 Jul; 29(7):708-16. PubMed ID: 27102344
[TBL] [Abstract][Full Text] [Related]
13. Epigenetic subclassification of meningiomas based on genome-wide DNA methylation analyses.
Kishida Y; Natsume A; Kondo Y; Takeuchi I; An B; Okamoto Y; Shinjo K; Saito K; Ando H; Ohka F; Sekido Y; Wakabayashi T
Carcinogenesis; 2012 Feb; 33(2):436-41. PubMed ID: 22102699
[TBL] [Abstract][Full Text] [Related]
14. DNA methylation profiling to predict recurrence risk in meningioma: development and validation of a nomogram to optimize clinical management.
Nassiri F; Mamatjan Y; Suppiah S; Badhiwala JH; Mansouri S; Karimi S; Saarela O; Poisson L; Gepfner-Tuma I; Schittenhelm J; Ng HK; Noushmehr H; Harter P; Baumgarten P; Weller M; Preusser M; Herold-Mende C; Tatagiba M; Tabatabai G; Sahm F; von Deimling A; ; Zadeh G; Aldape KD
Neuro Oncol; 2019 Jul; 21(7):901-910. PubMed ID: 31158293
[TBL] [Abstract][Full Text] [Related]
15. Sporadic multiple meningiomas harbor distinct driver mutations.
Juratli TA; Prilop I; Saalfeld FC; Herold S; Meinhardt M; Wenzel C; Zeugner S; Aust DE; Barker FG; Cahill DP; Brastianos PK; Santagata S; Schackert G; Pinzer T
Acta Neuropathol Commun; 2021 Jan; 9(1):8. PubMed ID: 33407897
[No Abstract] [Full Text] [Related]
16. DNA methylation profiling of meningiomas highlights clinically distinct molecular subgroups.
Singh J; Sharma R; Shukla N; Narwal P; Katiyar A; Mahajan S; Sahu S; Garg A; Sharma MC; Suri A; Sarkar C; Suri V
J Neurooncol; 2023 Jan; 161(2):339-356. PubMed ID: 36564673
[TBL] [Abstract][Full Text] [Related]
17. Advances in Molecular Classification and Therapeutic Opportunities in Meningiomas.
Cordova C; Kurz SC
Curr Oncol Rep; 2020 Jul; 22(8):84. PubMed ID: 32617743
[TBL] [Abstract][Full Text] [Related]
18. Histological classification and molecular genetics of meningiomas.
Riemenschneider MJ; Perry A; Reifenberger G
Lancet Neurol; 2006 Dec; 5(12):1045-54. PubMed ID: 17110285
[TBL] [Abstract][Full Text] [Related]
19. Intraventricular meningiomas frequently harbor NF2 mutations but lack common genetic alterations in TRAF7, AKT1, SMO, KLF4, PIK3CA, and TERT.
Jungwirth G; Warta R; Beynon C; Sahm F; von Deimling A; Unterberg A; Herold-Mende C; Jungk C
Acta Neuropathol Commun; 2019 Aug; 7(1):140. PubMed ID: 31470906
[TBL] [Abstract][Full Text] [Related]
20. Classification of meningiomas-advances and controversies.
Harter PN; Braun Y; Plate KH
Chin Clin Oncol; 2017 Jul; 6(Suppl 1):S2. PubMed ID: 28595423
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
